Xeris Biopharma (XERS) officer sells 16,667 shares in Rule 10b5-1 trade
Rhea-AI Filing Summary
Xeris Biopharma Holdings officer Beth Hecht reported an open-market sale of Company stock. She sold 16,667 shares of common stock at a weighted average price of $6.0588 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, she continues to hold 1,176,506 shares directly.
Positive
- None.
Negative
- None.
Insights
Routine 10b5-1 sale of a small portion of existing holdings.
The filing shows officer Beth Hecht sold 16,667 shares of Xeris Biopharma common stock at a weighted average price of $6.0588 per share in an open-market transaction.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a scheduled, programmatic disposition rather than a discretionary trade. Following the sale, she still directly owns 1,176,506 shares, suggesting the transaction represents only a modest portion of her position.
Insider Trade Summary 10b5-1
Net Seller: 16,667 shares
Net Sell
1 txn
Insider
Hecht Beth
Role
See Remarks
Sold
16,667 shs ($101K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 16,667 | $6.0588 | $101K |
Holdings After Transaction:
Common Stock — 1,176,506 shares (Direct)
Footnotes (2)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.980 to $6.180, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Key Figures
Shares sold: 16,667 shares
Weighted average sale price: $6.0588 per share
Post-transaction holdings: 1,176,506 shares
+1 more
4 metrics
Shares sold
16,667 shares
Open-market sale of common stock
Weighted average sale price
$6.0588 per share
Common stock sale on 2026-06-01
Post-transaction holdings
1,176,506 shares
Common stock directly owned after sale
Price range
$5.980 to $6.180
Range of sale prices across multiple trades
Key Terms
Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4
4 terms
Rule 10b5-1 trading plan regulatory
"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"disclosed in the Form 4 insider trading report"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Xeris Biopharma (XERS) report for Beth Hecht?
Xeris Biopharma reported that officer Beth Hecht sold 16,667 shares of common stock. The open-market sale was executed at a weighted average price of $6.0588 per share, and it was carried out under a pre-arranged Rule 10b5-1 trading plan.
Was the Xeris Biopharma (XERS) insider sale by Beth Hecht under a Rule 10b5-1 plan?
Yes, the filing states the transaction was effected under a Rule 10b5-1 trading plan. Such plans are pre-arranged programs that schedule trades in advance, often reducing the significance of trade timing as a signal of insider sentiment.
What type of transaction did Xeris Biopharma (XERS) disclose for Beth Hecht?
The company disclosed an open-market sale of common stock by officer Beth Hecht. The Form 4 identifies the transaction code as “S,” indicating a sale, and describes it as a sale in the open market or a private transaction of 16,667 shares.